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In Crohn’s disease, mild gastrointestinal bleeding often occurs; however massive gastrointestinal hemorrhage, 
which can have a dramatic effect on a patient’s vital sign, is rare. This could result in potentially life-threatening compli-
cations, which can lead to death. Massive hemorrhagic Crohn’s disease is not well known and for this reason, they 
are a diagnostic and therapeutic challenge. Various diagnostic and therapeutic methods are currently being devel-
oped and used. The surgical method is often used only as a last measure since this approach has the risk of serious 
complications that may endanger patients. However, if massive bleeding continues even after all therapeutic meth-
ods are used, the surgical method must be implemented. In this case, all therapeutic methods were found to be in-
effective; therefore, surgery was used as a last option. Ultimately, the surgical method was found to be successfully 
used to treat life-threatening hemorrhagic Crohn’s disease. (Pediatr Gastroenterol Hepatol Nutr 2013; 16: 53∼60)
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INTRODUCTION
　Crohn’s disease is an inflammatory disease of un-
known etiology and can occur in any gastrointestinal 
tract from the oral cavity to the anus [1]. This disease 
brings about complications, including intestinal 
stricture, fistula and gastrointestinal bleeding. 
Whereas mild gastrointestinal bleeding is a common 
manifestation, acute and severe lower gastro-
intestinal bleeding, which significantly lowers blood 
pressure, is rare. Massive hemorrhagic Crohn’s dis-
ease is not well known and for this reason, it repre-
sents a diagnostic and therapeutic challenge.
　One of the common characteristic of Crohn’s dis-
ease is that it repetitively shows recurring and wor-
sening clinical progress and no clear treatment is de-
veloped for now [2,3]. Due to the diverse clinical pre-
sentations and complications of this disease, various 
therapeutic methods have been used and new treat-
ments based on clinical studies are being suggested. 
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Among these, medical therapy, endoscopic therapy 
and arterial embolization have been reported to be 
effective in controlling the bleeding of hemorrhagic 
Crohn’s disease [4,5]. However, if massive bleeding 
continues even after attempting these various ther-
apeutic methods, the surgical method must be used. 
　In this study, a 13 year old with Crohn’s disease 
was admitted to the hospital and all methods, in-
cluding medical therapy, exclusive enteral nutrition 
(EEN), angiographic intervention were attempted 
without success. Severe hemorrhagic gastrointesti-
nal bleeding continued and without any further op-
tions, surgical therapy was performed. This mode of 
treatment eventually lead to successful controlled 
bleeding. This case is even more significant because 
it is extremely rare for massive hemorrhagic Crohn’s 
disease to occur among children. In addition, this 
was the first case where severe gastrointestinal 
bleeding was the presenting symptom of Crohn’s 
disease.
CASE REPORT
　A 13 years old boy was admitted to the hospital be-
cause of gross hematochezia. There was nothing sig-
nificant in the patient’s past medical history over the 
past 6 months. He reported suffering from inter-
mittent diarrhea and abdominal pain. Also, he went 
from 47 kg to 40 kg during the course of 3 months. He 
was initially believed to have hematochezia and 
therefore a colonoscopy was performed. After the co-
lonoscopy, he was sent to our hospital with suspicion 
of inflammatory bowel disease. At his first visit, his 
blood pressure, pulse rate, respiratory rate, body 
temperature, height and body weight were 110/65 
mm/Hg, 90/min, 20/min, 36.5oC, 164.2 cm (25-50 p) 
and 40 kg (5-10 p), respectively. He appeared chroni-
cally ill and was pale. The physical examination upon 
admission showed slight pain and tenderness at the 
peri-umbilical region without muscular guarding. 
His bowel sounds were normal and the rectal exami-
nation revealed an empty ampulla with no other pe-
culiar symptoms regarding peri-anal abscess or 
fistula. The laboratory investigations during the first 
exam were as follows: erythrocyte sedimentation 
rate (ESR) 84 mm/h, C-reactive protein 106 mg/L 
(normal 0-8 mg/L), albumin 2.8 g/dL, prothrombin 
time 11.5 sec, partial thromboplastin time 28.1 sec, 
hemoglobin 10.4 g/dL, leucocytes 9.8×109/L with 
normal leukocyte differentiation, and thrombocytes 
489×109/L. A stool occult blood test was also per-
formed and found to be positive. The colonoscopy 
showed an inflammatory bowel with multiple linear 
deep ulcerations, cobble stone appearances and 
pseudo-polyps (Fig. 1). In addition, in the MRI en-
terography, a diffuse bowel wall thickening was ob-
served at the distal to terminal ileum, cecum and rec-
tosigmoid colon. Accordingly, he was diagnosed 
with Crohn’s disease. His Pediatric Crohn’s disease 
Activity Index (PCDAI) score was 68. Initially, in-
duction therapy was performed with oral steroids 
(30 mg/day) and Azathioprine (100 mg/day). He was 
also given 8weeks of EEN with a polymeric formula 
(Monowell 2,000 mL daily). After medical therapy, 
the abdominal pain has declined slightly and the 
ESR and C-reactive protein (CRP) was reduced but 
intermittent mild bloody stools were still observed. 
After the 10th day of hospitalization, approximately 
1,000 mL of a fresh bloody stool and dizziness with 
about a 10-second loss of consciousness had 
occurred. At this time, his blood pressure had drop-
ped to 80/40 mmHg. In addition, his hemoglobin lev-
els dropped from 10.4 g/dL to 7.6 g/dL. Accordingly, 
6 units blood transfusion was performed over a 24 
hour time period. After the blood transfusion, his vi-
tal signs had stabilized. Based on the patient’s past 
history and the colonoscopy data, we presumed that 
this gastrointestinal hemorrhage was caused by 
Crohn’s disease. At that point, oral steroid treatment 
was changed to intravenous steroids and the patient 
was placed under conservative care. However, even 
after 10 days, due to over 500 mL of continuous mas-
sive hematochezia and repetitive hemoglobin drop, 
blood transfusion was needed. Thus, a bleeding fo-
cus evaluation was performed. From the GI bleeding 
scintigraphy, the radiotracer was found to be up tak-
en in the mid to left upper quadrant in the abdomen 
and no abnormal signs were observed in the abdo-
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Fig. 1. The 1st colonoscopy. 
Multiple linear deep ulcera-
tions, cobble stone appearance
and pseudo-polyp at terminal 
ileum, which are consistent 
with Crohn’s disease.
men CT. A duodenal ulcer was observed in the upper 
endoscopy but no other acute findings were made. A 
colonoscopy was then performed and multiple active 
ulcerations in the distal ileum and inflammatory pol-
yps and cobble stone appearance were found (Fig. 2). 
Ulcers and bleeding was also expected to be found; 
however, current active bleeding was not observed 
and no other bleeding focus was present. For 3 
weeks, even with steroid induction and azathioprine 
therapy, mucosal healing was not successful. The 
PCDAI score was also 60, which was indicative of 
continued severe disease activity. Since steroid ther-
apy was ineffective, infliximab infusion (5 mg/kg) 
was initiated. On the 21st day, a superior mesenteric 
angiography was performed. In this test, no active 
bleeding was observed; however, a hypervascular 
blush, which caused by inflammatory changes, was 
observed near the proximal ascending colon and 
ileocecal (IC) valve. To account for this, 2 superior 
mesenteric arteries were selected using a micro-
catheter and gel foam arterial embolization was suc-
cessfully performed (Fig. 3 and 4). A hematochezia 
was found nowhere and the PCDAI score had de-
creased by 20 points. Starting on the 27th day, mu-
cosal healing and bleeding was thought to be well 
managed from infliximab infusion and embolization 
and maintenance therapy was performed using me-
salazine (4,000 mg/day). 2 weeks after the first in-
fliximab injection, which corresponded to the 34th 
day of hospitalization, valve,  a second infusion of in-
fliximab (5 mg/kg) was done. However, 650 mL of 
massive hematochezia was observed on the 35th day 
of hospitalization. For the first 24 hours, the patient 
was given 2 units of blood. However, even with active 
transfusion, the massive rectal hemorrhage con-
tinued and his hemoglobin levels dropped from 12.6 
gm/dL to 11.6 gm/dL. At this point, we deemed it 
necessary to perform surgery. To examine the precise 
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Fig. 3. The 1st superior mesenteric angiography shows 
increased focal staining in the ileocecal valve and proximal 
ascending colon.
Fig. 2. The 2nd colonoscopy.
Current active bleeding was 
not observed and no other 
bleeding focus was found in 
the scope.
Fig. 4. Two superior mesenteric artery branches were selected 
and arterial embolization was performed.
operation scale, a second angiography was performed 
before the operation. The superior mesenteric artery 
angiography showed a hypervascular blush near the 
proximal ascending colon and IC valve; however, no 
active bleeding was observed (Fig. 5). On the 36th day 
of hospitalization, an ileocecectomy and hand sewn 
end to side anastomosis were performed. During the 
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Fig. 5. The 2nd superior mesenteric angiography shows a 
hypervascular blush in the ileocecal valve and proximal 
ascending colon.
Fig. 6. Specimen from ileocecal resection. Erythematous and 
multiple ulceration, transmural inflammation with perforation 
and small non-caseating granuloma are shown, a condition that
is compatible with Crohn’s disease.
operation, wall edema and inflammation was found 
on the IC valve which was about 30 cm deep into the 
terminal ileum. An ileostomy was initiated to ob-
serve the inside of the lumen and a cobble like ap-
pearance, mucosal ulceration and dark blood clot 
was found. The lumen of the cecum was relatively 
clean and inflammation was not severe. Although a 
single bleeding point was not identified, the hemor-
rhage presumably originated from the diffusely mul-
tifocal ulcerated ileal mucosa. Approximately 30 cm 
of the terminal ileum and cecum together were cut 
and an ileocecectomy was performed as well as a 
hand swen end to side anastomosis (Fig. 6). 
According to the pathologic examination, the ileoce-
cum was erythematous and multiple ulceration, 
transmural inflammation with perforation and 
small non-caseating granuloma were observed, a 
condition that was compatible with Crohn’s disease. 
No colonic diverticula were identified. After the ileo-
cecectomy, the patient’s bleeding promptly ceased 
and he did not require additional blood transfusions. 
On the 6th postoperative day, a clear liquid diet was 
started and on the 7th postoperative day, a dark 
brown colored stool was evident; however, no more 
hemorrhage episodes occurred and the abdominal 
pain was managed, which resulted in a steady in-
crease in food consumption. The daily dose of pre-
dnisolone was set at 30 mg/day initially and was de-
creased according to the clinical activity of the 
disease. On the 12th postoperative day, the PCDAI 
score was 15 and the wound had cleared; therefore, 
the patient was discharged. Currently, the patient is 
in maintenance therapy and receives only 
infliximab. After the hospitalization, the PCDAI 
score remained below 10 and disease activity was 
controlled. The patient has no recurrence of bleeding 
or evidence of Crohn's disease and is currently in 
good condition. 
DISCUSSION 
　Hematochezia is one of common manifestations of 
Crohn’s disease and occurs in 45% of patients with 
this disease [6]; however massive gastrointestinal 
hemorrhage, which could cause a decrease in blood 
pressure, is a rare complication that occurs in only 
about 0.9% to 2.5% of patients with Crohn’s disease 
[4,7]. There is no exact protocol regarding treatment 
of massive hemorrhagic Crohn’s disease, which is 
rare. Original medical literature and works still pro-
vide insufficient information on massive hemor-
rhagic Crohn’s disease patients [8]. 
　A conservative approach has been suggested for 
initial treatment of these patients [9]. However, if 
bleeding cannot be controlled even with medical 
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therapy and conservative care, additional acute ther-
apeutic interventions are needed. Several ap-
proaches such as endoscopic treatment, angio-
graphic intervention and surgical resection have 
been used to treat this disease [10,11]. 
　For a majority of life threatening lower gastro-
intestinal hemorrhage patients, emergent surgical re-
section is performed as a standard treatment [4]. 
Cirocco et al. [7] reported that surgical resection of-
fered excellent palliation, with low mortality (3%) 
and a low rebleeding rate (5.7%), when compared 
with those patients managed medically (38%).
　However, it has been found out that Crohn’s dis-
ease can easily reoccur and surgical resection does 
not affect the recurrence rate of Crohn’s disease [12]. 
Also, surgery increases the risk of major complica-
tions, such as post operative bowel obstruction, in-
tra-abdominal and wound infections, anastomotic 
leakages, and fistulas [13]. From repetitive bowel re-
section, serious complications, such as short bowel 
syndrome can occur, which could result in a variable 
amount of diarrhea and metabolic upset [2]. As de-
scribed above, there are many limitations to the sur-
gical method; thus, various therapeutic methods 
should be used together.
　Non-surgical methods are preferred if an oper-
ation is not needed. Non-surgical methods include 
angiographic embolization, arterial vasopressin 
therapy, EEN and infliximab [5,10,14]. 
　Superselective embolization has been used to pre-
vent surgical resection in hemorrhagic Crohn’s dis-
ease [4]. This therapeutic intervention with emboli-
zation was shown to have a downside: risk for in-
testinal infarction. However, with recent advances in 
interventional radiological techniques, developed 
microcatheters and embolic agents and microcoils, 
complications such as infarction have significantly 
decreased [8]. Therefore, angiographic embolization 
can be used as an initial treatment strategy for hem-
orrhagic Crohn’s disease. It has been reported that 
angiographic embolization has a success rate ranging 
from 81% to 93%, with a mortality rate between 0% 
and 7% [5]. 
　The availability of arterial vasopressin therapy to 
control bleeding during a massive hemorrhage in 
Crohn’s disease has also been reported [15]. Even 
though vasopressin infusion was not sufficient to 
cease the hemorrhage and control the bleeding com-
pletely, the injection could provide time for stabiliza-
tion and full resuscitation and thus it could be uti-
lized to provide more time for the operation [16]. 
Another benefit of using vasopressin is that it can be 
selectively used in diffuse lesions and cases in which 
super selective catheterization is not technically pos-
sible [6]. 
　EEN is also currently used for the treatment of 
Crohn’s disease and it has been shown to have sev-
eral benefits. EEN was first performed in 1973 by 
Voitk et al. [14] to reinforce the nutritional state of 
patients with Crohn’s disease who were resistive to 
diverse types of medications. After the first report of 
remission of induction of this patient, the potential 
of using EEN to treat Crohn’s disease was inves-
tigated [17]. Positive effects such as mucosal healing 
and nutritional improvements due to EEN treatment 
have been reported. 
　The use of infliximab for treatment of this disease 
is also controversial. Typically, for refractory Crohn’s 
disease, which original medications aren’t effective, 
and recurrable gastrointestinal bleeding, Infliximab 
could have possible benefits in regards to treatment 
[10,18,19]. Infliximab can induce rapid and sus-
tained mucosal healing [10]. For instance, according 
to one study, steroids only have a 29% incidence of 
mucosal healing, whereas infliximab offers a theo-
retical advantage over steroids given its high rate of 
mucosal healing, which is about 50% [20]. In addi-
tion, infliximab has been shown to suppress and re-
solve severe acute bleeding [10]. Because this ther-
apy has very rapid effects, and may be used instead of 
surgical resection for uncontrolled bleeding, we be-
lieve that infliximab therapy should be considered 
for acute and massive GI bleeding in Crohn’s disease 
before surgery [10]. 
　As described above, various methods to treat 
Crohn’s disease with gastrointestinal bleeding with-
out any surgical procedure have been suggested; 
however, if medical treatment fails or bleeding con-
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tinues even with intervention, bowel resection 
through surgical therapy should be performed. 
Crohn’s diseases with bleeding can be controlled in 
more than 50% of all cases by the use of medical 
treatment. Among these, 30% will reoccur and the 
surgical methods must often be performed to control 
bleeding [6]. Therefore, when recurrent major hem-
orrhage or severe bleeding is found, bowel resection 
through the surgical method should be considered. 
　In this case, severe gastrointestinal bleeding 
which almost unstabilized vital sign as a first symp-
tom was observed at 13 years old Crohn’s disease 
patient. After a massive blood transfusion, various 
therapeutic methods such as EEN and medical treat-
ment were used; however, none were effective. 
Accordingly, diagnostic methods, such as colono-
scopy upper endoscopy, GI bleeding scintigraphy 
and angiography were used to localize the bleeding 
point and bleeding was instantly ceased by arterial 
embolization and infliximab therapy. However, a 
massive hemorrhage soon recurred; thus, operation 
was performed and the bleeding was eventually suc-
cessfully controlled. 
　In general, the surgical method is not always the 
first choice for the treatment of patients with mas-
sive hemorrhagic Crohn’s disease because this treat-
ment option can also result in many serious compli-
cations that could endanger the patient. However, if 
all other therapeutic methods are not effective, the 
surgical method should be considered as a final 
option. 
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